These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21697498)

  • 21. Identification and characterization of loop7 motif and its role in regulating biological function of human APOBEC3G through molecular modeling and biological assay.
    Zhai C; Ma L; Zhang Z; Ding J; Wang J; Zhang Y; Li X; Guo F; Yu L; Zhou J; Cen S
    Acta Pharm Sin B; 2017 Sep; 7(5):571-582. PubMed ID: 28924551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.
    Derse D; Hill SA; Princler G; Lloyd P; Heidecker G
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2915-20. PubMed ID: 17299050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA.
    Guo F; Cen S; Niu M; Yang Y; Gorelick RJ; Kleiman L
    J Virol; 2007 Oct; 81(20):11322-31. PubMed ID: 17670826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
    Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
    J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.
    Cho SJ; Drechsler H; Burke RC; Arens MQ; Powderly W; Davidson NO
    J Virol; 2006 Feb; 80(4):2069-72. PubMed ID: 16439564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia.
    Jin X; Brooks A; Chen H; Bennett R; Reichman R; Smith H
    J Virol; 2005 Sep; 79(17):11513-6. PubMed ID: 16103203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F.
    Yang Y; Guo F; Cen S; Kleiman L
    Virology; 2007 Aug; 365(1):92-100. PubMed ID: 17459442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Wang X; York IA; Zheng YH
    J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study.
    Bernacchi S; Henriet S; Dumas P; Paillart JC; Marquet R
    J Biol Chem; 2007 Sep; 282(36):26361-8. PubMed ID: 17609216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains.
    Hakata Y; Landau NR
    J Biol Chem; 2006 Dec; 281(48):36624-31. PubMed ID: 17020885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes.
    Grant M; Larijani M
    AIDS Res Ther; 2017 Sep; 14(1):44. PubMed ID: 28893290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.
    Noguera-Julian M; Cozzi-Lepri A; Di Giallonardo F; Schuurman R; Däumer M; Aitken S; Ceccherini-Silberstein F; D'Arminio Monforte A; Geretti AM; Booth CL; Kaiser R; Michalik C; Jansen K; Masquelier B; Bellecave P; Kouyos RD; Castro E; Furrer H; Schultze A; Günthard HF; Brun-Vezinet F; Metzner KJ; Paredes R;
    Clin Microbiol Infect; 2016 Feb; 22(2):191-200. PubMed ID: 26482266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of Vif-induced APOBEC3G degradation using an alpha-complementation assay.
    Fang L; Landau NR
    Virology; 2007 Mar; 359(1):162-9. PubMed ID: 17049578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus.
    Peng ZG; Zhao ZY; Li YP; Wang YP; Hao LH; Fan B; Li YH; Wang YM; Shan YQ; Han YX; Zhu YP; Li JR; You XF; Li ZR; Jiang JD
    Hepatology; 2011 Apr; 53(4):1080-9. PubMed ID: 21480314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
    Pillai SK; Wong JK; Barbour JD
    Retrovirology; 2008 Mar; 5():26. PubMed ID: 18339206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo.
    Kourteva Y; De Pasquale M; Allos T; McMunn C; D'Aquila RT
    Virology; 2012 Aug; 430(1):1-9. PubMed ID: 22579353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif.
    Nakano Y; Aso H; Soper A; Yamada E; Moriwaki M; Juarez-Fernandez G; Koyanagi Y; Sato K
    Retrovirology; 2017 May; 14(1):31. PubMed ID: 28482907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.